NeuroSense Therapeutics Ltd.
NRSNDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
PrimeC
Alzheimer Disease
Fixed dose combination Ciprofloxacin/Celecoxib
Amyotrophic Lateral Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PrimeC | Phase 2 | Alzheimer Disease | - | - |
Fixed dose combination Ciprofloxacin/Celecoxib | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in NeuroSense Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in NeuroSense Therapeutics Ltd.'s (NRSN) pipeline across Phase 2. Its lead program is PrimeC (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NeuroSense Therapeutics Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for NeuroSense Therapeutics Ltd. (NRSN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NRSN biotech catalysts?→
Add NRSN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NeuroSense Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.